research 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
Search
for
Sort by
Research
450-480 / 1000+ resultsresearch Experiences with Smo antagonist vismodegib for the treatment of locally advanced basal cell carcinoma
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
research New developments in the treatment of systemic lupus erythematosus
New treatments for lupus show promise, but more research is needed, especially for children.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Pleural Effusion Associated With Divalproex Sodium
Divalproex sodium can cause pleural effusion, which stops when the drug is discontinued.
research Immediate and Delayed Complications of Dexamethasone Cyclophosphamide Pulse (DCP) Therapy
DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.
research ALOPECIA UNIVERSALIS TREATED WITH ORAL CYCLOSPORINE A AND PREDNISOLONE: IMMUNOLOGIC STUDIES
Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.
research Uses of Dupilumab in Dermatology: A Systematic Review of the Randomized Controlled Trials
Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
research Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
research Quantification of the Vitamin D Receptor−Coregulator Interaction
Vitamin D receptor binds similarly to natural and synthetic ligands, affecting gene regulation.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report
Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
research PSS33 REAL-LIFE DOSING OF BIOLOGICS IN PLAQUE PSORIASIS—A GERMAN SURVEY
Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.
research Combination of Low-Dose Isotretinoin and Pulsed Oral Azithromycin in the Management of Moderate to Severe Acne
Low-dose isotretinoin combined with pulsed azithromycin cleared acne in most patients, with mild side effects.
research The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII)
Intravenous and oral calcium effectively treated vitamin D dependent rickets type II, improving growth and bone health.
research Treatment of androgenic disorders with dexamethasone: Dose-response relationship for suppression of dehydroepiandrosterone sulfate
Lower doses of dexamethasone can safely reduce high DHEAS levels in women with androgenic disorders.
research 44391 ICI Therapy Toxicities in Psoriasis
ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
research Folliculitis decalvans responsive to tofacitinib: A case series
Tofacitinib may effectively treat folliculitis decalvans.
research Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
Deucravacitinib helped a man regrow hair and improve psoriasis.
research 0475 High-dose UVA-1 therapy improves patient-reported outcomes and clinical scores in patients with sclerosing skin disease
High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
research Deoxycorticosterone’s anticonvulsant effects in infant rats are blocked by finasteride, but not by indomethacin
Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.
research A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
research Irish dermatologists’ experience with JAK inhibitors in alopecia areata
Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
research Drug Discovery Today: Therapeutic Strategies - 2006 Editorial
The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.